Federal award (PURCHASE ORDER, fiscal year 2024)
Recipient: BOSTON SCIENTIFIC CORP
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Defense Health Agency
Period of performance: 2025-10-01 to 2026-09-30
Current total value of award: $552770
Description: TRANSARTERIAL RADIOEMBOLIZATION USING YTTRIUM-90 MICROSPHERES IS A THERAPEUTIC OPTION FOR PATIENTS WITH INTERMEDIATE-OR ADVANCED-STAGE HEPATOCELLULAR CARCINOMA, INCLUDING THOSE WITH RECURRENT OR INOPERABLE HEPATOCELLULAR CARCINOMA.